Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus

Aghdassi, Elaheh; David, W. L.; Morrison, Stacey; Hillyer, Lynn M.; Clarke, Shannon; Gladman, Dafna D.; Urowitz, Murray B.; Fortin, Paul R.

doi:10.1177/0148607110386378

Cited by 27 publications

(33 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a similar pattern of grouping of FFA species in the PCA was observed in rheumatoid arthritis patients by our group (24), differences among FFA species between patients and controls were not observed in the case of lupus. Interestingly, no differences in plasma FFA profiling were observed in a previous study with lupus patients (63), although slight alterations in the polyunsaturated fatty acids were reported in those with a previous history of CVD. Our results are, at least in part, in line with these findings, although differences in the experimental procedures between both studies are important.…”

Section: Discussionmentioning

confidence: 56%

Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus

et al. 2017

View full text Add to dashboard Cite

Metabolic impairments are a frequent hallmark of systemic lupus erythematosus (SLE). Increased serum levels of free fatty acids (FFA) are commonly found in these patients, although the underlying causes remain elusive. Recently, it has been suggested that factors other than inflammation or clinical features may be involved. The gut microbiota is known to influence the host metabolism, the production of short-chain fatty acids (SCFA) playing a potential role. Taking into account that lupus patients exhibit an intestinal dysbiosis, we wondered whether altered FFA levels may be associated with the intestinal microbial composition in lupus patients. To this aim, total and specific serum FFA levels, fecal SCFA levels, and gut microbiota composition were determined in 21 SLE patients and 25 healthy individuals. The Firmicutes to Bacteroidetes (F/B) ratio was strongly associated with serum FFA levels in healthy controls (HC), even after controlling for confounders. However, this association was not found in lupus patients, where a decreased F/B ratio and increased FFA serum levels were noted. An altered production of SCFA was related to the intestinal dysbiosis in lupus, while SCFA levels paralleled those of serum FFA in HC. Although a different serum FFA profile was not found in SLE, specific FFA showed distinct patterns on a principal component analysis. Immunomodulatory omega-3 FFA were positively correlated to the F/B ratio in HC, but not in SLE. Furthermore, divergent associations were observed for pro- and anti-inflammatory FFA with endothelial activation biomarkers in lupus patients. Overall, these findings support a link between the gut microbial ecology and the host metabolism in the pathological framework of SLE. A potential link between intestinal dysbiosis and surrogate markers of endothelial activation in lupus patients is supported, FFA species having a pivotal role.

show abstract

Section: Discussionmentioning

confidence: 56%

Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus

et al. 2017

View full text Add to dashboard Cite

show abstract

“…No entanto, alguns ensaios clínicos sugerem que a suplementação com essa classe de lipídeos pode representar terapia adicional ao tratamento farmacológico tradicional dessa doença devido às propriedades anti-inflamatórias. [17][18][19][20][21][22][23][24][25] Parece haver diferença nos níveis de ácidos graxos nas hemácias e no plasma de indivíduos com LES e naqueles sem a doença. No entanto, não se sabe se essa diferença ocorre devido à dieta inadequada ou à própria doença.…”

Section: ôMega-3 E Lúpus Erimatoso Sistêmicounclassified

“…Entretanto, essas diferenças não foram estatisticamente significativas. 23 Os baixos níveis de -3 poderiam contribuir para piora da inflamação já presente nesses pacientes, indicando que a suplementação do nutriente, por sua vez, contribuiria para melhora do perfil inflamatório e, consequentemente, da atividade da doença, como constatado por Elkan et al (2012) em estudo realizado com 114 pacientes com LES e 122 indivíduos sem a doença. Os autores verificaram que maiores níveis de EPA e DHA nas células do tecido adiposo de pacientes com LES foram negativamente associados com atividade da doença (medida pelo Systemic Lupus Erythematosus Disease Activity Index -SLEDAI) e presença de placas ateroscleróti-cas.…”

Section: ôMega-3 E Lúpus Erimatoso Sistêmicounclassified

“…[17][18][19][20][21][22][23][24][25] Essa classe de lipídeos está relacionada com a produção de eicosanoides com menor ação inflamatória do que os produzidos pelos ácidos graxos pertecentes à família -6, além da redução dos níveis séricos de citocinas inflamatórias e da ativação de linfócitos T.…”

Section: Considerações Finaisunclassified

“…No entanto, parece haver relação entre o consumo deste tipo de gordura e a diminuição das manifestaç ões e da atividade inflamatória da doença. [17][18][19][20][21][22][23][24][25] Os autores apresentam revisão da literatura científica sobre os efeitos dos ácidos graxos ômega-3 em pacientes com LES.…”

Section: Introductionunclassified

See 2 more Smart Citations

Ácidos graxos poli‐insaturados ômega‐3 e lúpus eritematoso sistêmico: o que sabemos?

Borges

Santos

Telles

et al. 2014

Revista Brasileira de Reumatologia

View full text Add to dashboard Cite

Various studies have demonstrated the impact of omega-3 fatty acids on the concentration of C reactive protein (CRP), pro-inflammatory eicosanoids, cytokines, chemokines and other inflammatory mediators. Therefore, the supplementation of these types of lipids may represent additional option treatment for chronic systemic diseases, such as Systemic Lupus Erythematous and other rheumatic diseases. The role of these lipids has not been well established, yet. However, it seems there is a direct relationship between its intake and the decrease of the disease clinical manifestations as well as of the inflammatory status of the patients. Thus, the aim of this manuscript is to present a thorough review on the effects of omega-3 fatty acids in patients with SLE. Bibliographic data set as the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) were searched using as key words: systemic lupus erythematous (SLE), polyunsaturated fatty acids omega-3, eicosapentanoic acid (EPA), docosahexanoic acid (DHA), antioxidants and diet. Manuscripts published up to September 2013 were included. There were 43 articles related to the topic, however only 15 pertained human studies, with three review articles and 12 clinical studies.

show abstract

Dietary Omega Polyunsaturated Fatty Acid Intake and Patient‐Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program

Charoenwoodhipong

Harlow

Marder

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Objective To examine associations between dietary intake of omega‐3 (n‐3; generally antiinflammatory) and omega‐6 (n‐6; generally proinflammatory) fatty acids and patient‐reported outcomes in systemic lupus erythematosus (SLE). Methods This study was based on the population‐based Michigan Lupus Epidemiology and Surveillance cohort. Estimates of n‐3 and n‐6 intake were derived from Diet History Questionnaire II items (past year with portion size version). Patient‐reported outcomes included self‐reported lupus activity (Systemic Lupus Activity Questionnaire [SLAQ]). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n‐3 and n‐6, as well as the n‐6:n‐3 ratio, and patient‐reported outcomes. Results Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4%) were African American, and the mean ± SD age was 52.9 ± 12.3 years. Controlling for potential confounders, the average SLAQ score was significantly higher by 0.3 points (95% confidence interval [95% CI] 0.1, 0.6; P = 0.013) with each unit increase of the n‐6:n‐3 ratio. Both lupus activity and Patient‐Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scores were lower with each 1‐gram/1,000 kcal increase of n‐3 fatty acids (SLAQ regression coefficient β = –0.8 [95% CI –1.6, 0.0]; P = 0.055; PROMIS sleep β = –1.1 [95% CI –2.0, –0.2]; P = 0.017). Higher n‐3 intakes were nonsignificantly associated with lower levels of depressive symptoms and comorbid fibromyalgia, and with higher quality of life, whereas results for the n6:n3 ratio trended in the opposite direction. Conclusion This population‐based study suggests that higher dietary intake of n‐3 fatty acids and lower n‐6:n‐3 ratios are favorably associated with patient‐reported outcomes in SLE, particularly self‐reported lupus activity and sleep quality.

show abstract

Alterations in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus

Abstract: SLE patients, regardless of their history of CVD, have altered plasma and RBC FA composition favoring inflammation. The use of prednisone was associated with differences in FA profile.

Cited by 27 publications

References 72 publications

Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus

Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus

Ácidos graxos poli‐insaturados ômega‐3 e lúpus eritematoso sistêmico: o que sabemos?

Dietary Omega Polyunsaturated Fatty Acid Intake and Patient‐Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program

Contact Info

Product

Resources

About